(Reuters) – Merck said on Thursday its experimental drug combination to treat some adults with HIV-1 infection met the main goal of two late-stage studies.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Want our Alerts FASTER than everyone else?
Serious traders know that every second counts in these markets. Text messages are about 7x faster than email. Get an edge on other traders by receiving our FREE instant Stock Alerts ahead of e-mail subscribers by subscribing to our Mobile Alert System.
We promise never to share your number with anyone else. Standard text messaging rates may apply.